Health ❯ Healthcare ❯ Biotechnology

Pharmaceuticals

Cystic Fibrosis Treatments Clinical Trials Drug Development Argenx SE Insmed Incorporated AI in Healthcare Cancer Treatment Regulatory Affairs Health Startups RNA Interference Chronic Obstructive Pulmonary Disease Drug Approval Process Antidotes ALS Treatments RNA-targeted Medicines Rare Diseases Autoimmune Therapies Biopharmaceutical Companies Biotech Companies Immunotherapy HIV Treatment Regeneron Therapeutic Programs Immunotherapy Companies Muscle Preservation Biopharma Mergers B-cell Mediated Diseases Antibody Therapy Safety Regulations

Amgen's Cash Strength Versus Moderna's mRNA Pivot

The comparison shows whether steady, cash-generating commercial scale or a pipeline-driven recovery will best reward shareholders.

Baron Capital Reaffirms Long-Term Bullish View on Health Care and Repositions Fund

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

ClearBridge Adds ATI as SMID Growth Strategy Trails Benchmark

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Atara Investors Urged to Seek Lead Role in Securities Case Ahead of Deadline

Atara Faces Investor Class Action Over FDA Rejections of EBVALLO

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

Investor Class Actions Target Atara Over FDA Setbacks to EBVALLO

Artisan Mid Cap Fund Tops Benchmark in Q3, Shifts Toward Defense and Industrials

PGIM Jennison’s Q2 Letter Details Health-Care Slide, Portfolio Shifts and Company Catalysts

Cytokinetics Hit With Securities Class Action Over Aficamten Timeline Disclosures

Biotech Veterans Launch Corsera Health to Develop a Once‑Yearly RNAi Heart Prevention Shot